2013 Highlights in NSCLC

 

The aim of this evaluation form is to gain your feedback, in order to maintain high educational standards and provide a reference for continuous improvement. Please indicate which rating reflects your answer.

Questions marked with are required.

1. Did your undertaking of this E-Learning module provide a general update on novelties in the treatment of patients with non-small-cell lung cancer and put the clinically meaningful findings into perspective? (1-not at all; 5-absolutely)

2. Did your undertaking of this E-Learning module provide an update on the latest findings related to mutations testing? (1-not at all; 5-absolutely)

3. Did your undertaking of this E-Learning module provide an update on the latest clinical research findings on targeted therapies, including patients with EGFR mutations, approaches to overcome ALK resistance, antiangiogenic treatments, immunotherapies and therapies that target other molecules? (1-not at all; 5-absolutely)

4. Please, provide your overall rating of the quality of the education offered by this E-Learning module. (1-poor; 5-excellent)

5. How would you rate the interactivity level offered in the E-Learning material? (1-poor; 5-excellent)

6. Was the information useful and relevant to your work and practice? (1-not at all; 5-absolutely)

7. Do you feel that the information presented was well balanced and supported by adequate evidence? (1-not at all; 5-absolutely)

8. If you would like to add your personal comments or make suggestion to improve future ESMO E-Learning material, please write in the box below: